All In Biotech

Drug Trial Radar · NCT04949841

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials

A Phase 3 Extension Trial of DELTA 1 and DELTA 2 to Evaluate the Long-term Safety of a Twice-daily Treatment With Delgocitinib Cream 20 mg/g as Needed for up to 36 Weeks in Adult Subjects With Chronic Hand Eczema (DELTA 3)

Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

801

Actual

Start

Aug 23, 2021

Primary completion

Sep 18, 2023

Study completion Sep 18, 2023

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jul 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this extension trial is to evaluate the long-term safety of delgocitinib. Subjects will visit the clinic every 4 week to assess the safety and efficacy of the treatment, until Week 36. A final follow-up phone call is planned on Week 38.

Conditions

  • Chronic Hand Eczema

Interventions

  • DelgocitinibDrug

    Delgocitinib cream 20 mg/g

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment-emergent Adverse Events From Baseline up to Week 38Time frame: From baseline up to Week 38

Locations

95 sites in 10 countries. Site status is shown where the registry gives one.

  • LEO Investigational Site

    Brussels, Belgium

  • LEO Investigational Site

    Ghent, Belgium

  • LEO Investigational Site

    Kortrijk, Belgium

  • LEO Investigational Site

    Leuven, Belgium

  • LEO Investigational Site

    Loverval, Belgium

  • LEO Investigational Site

    Maldegem, Belgium

  • LEO Investigational Site

    Calgary, Alberta, Canada

  • LEO Investigational Site

    Calgary, Alberta, Canada

  • LEO Investigational Site

    Edmonton, Alberta, Canada

  • LEO Investigational Site

    Edmonton, Alberta, Canada

  • LEO Investigational Site

    Surrey, British Columbia, Canada

  • LEO Investigational Site

    Vancouver, British Columbia, Canada

  • LEO Investigational Site

    Fredericton, New Bruswick, Canada

  • LEO Investigational Site

    Ajax, Ontario, Canada

  • LEO Investigational Site

    Cobourg, Ontario, Canada

  • LEO Investigational Site

    Etobicoke, Ontario, Canada

  • LEO Investigational Site

    Hamilton, Ontario, Canada

  • LEO Investigational Site

    Kingston, Ontario, Canada

  • LEO Investigational Site

    London, Ontario, Canada

  • LEO Investigational Site

    Markham, Ontario, Canada

  • LEO Investigational Site

    Toronto, Ontario, Canada

  • LEO Investigational Site

    Toronto, Ontario, Canada

  • LEO Investigational Site

    Waterloo, Ontario, Canada

  • LEO Investigational Site

    Windsor, Ontario, Canada

  • LEO Investigational Site

    Montreal, Quebec, Canada

  • LEO Investigational Site

    Aarhus N, Denmark

  • LEO investigational Site

    Copenhagen, Denmark

  • LEO Pharma Investigational Site

    Hellerup, Denmark

  • LEO Investigational Site

    Bordeaux, France

  • LEO Investigational Site

    Dijon, France

  • LEO Investigational Site

    Le Mans, France

  • LEO Investigational Site

    Lille, France

  • LEO Investigational Site

    Martigues, France

  • LEO Pharma Investigational Site

    Nantes, France

  • LEO Investigational Site

    Nice, France

  • LEO Investigational Site

    Nice, France

  • LEO Investigational Site

    Paris, France

  • LEO Investigational Site

    Reims, France

  • LEO Investigational Site

    Toulouse, France

  • LEO Investigational Site

    Aachen, Germany

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.